216 related articles for article (PubMed ID: 30185657)
1. Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.
Abikhair Burgo M; Roudiani N; Chen J; Santana AL; Doudican N; Proby C; Felsen D; Carucci JA
JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185657
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.
Abikhair M; Mitsui H; Yanofsky V; Roudiani N; Ovits C; Bryan T; Oberyszyn TM; Tober KL; Gonzalez J; Krueger JG; Felsen D; Carucci JA
JCI Insight; 2016 Jun; 1(8):e86434. PubMed ID: 27699266
[TBL] [Abstract][Full Text] [Related]
3. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma.
Zhang S; Fujita H; Mitsui H; Yanofsky VR; Fuentes-Duculan J; Pettersen JS; Suárez-Fariñas M; Gonzalez J; Wang CQ; Krueger JG; Felsen D; Carucci JA
PLoS One; 2013; 8(5):e62154. PubMed ID: 23667456
[TBL] [Abstract][Full Text] [Related]
4. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line.
Frost ER; Ford EA; Peters AE; Reed NL; McLaughlin EA; Baker MA; Lovell-Badge R; Sutherland JM
Reprod Fertil Dev; 2020 Aug; 32(12):1027-1039. PubMed ID: 32758351
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients.
Kosmidis M; Dziunycz P; Suárez-Fariñas M; Mühleisen B; Schärer L; Läuchli S; Hafner J; French LE; Schmidt-Weber C; Carucci JA; Hofbauer GF
J Immunother; 2010 Jun; 33(5):538-46. PubMed ID: 20463594
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 up-regulated modulator of apoptosis (PUMA) in non-melanoma skin cancer of long-term immunosuppressed solid organ transplant recipients compared to immunocompetent patients.
Neuberger A; Menzer C; Volk N; Enk AH; Hadaschik EN; Lonsdorf AS
Eur J Dermatol; 2021 Oct; 31(5):609-615. PubMed ID: 34903507
[TBL] [Abstract][Full Text] [Related]
8. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
9. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
10. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate.
Mühleisen B; Petrov I; Gächter T; Kurrer M; Schärer L; Dummer R; French LE; Hofbauer GF
Histopathology; 2009 Jul; 55(1):67-76. PubMed ID: 19614769
[TBL] [Abstract][Full Text] [Related]
11. An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
Campia I; Buondonno I; Castella B; Rolando B; Kopecka J; Gazzano E; Ghigo D; Riganti C
PLoS One; 2015; 10(5):e0126159. PubMed ID: 25955018
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.
Arumugam A; Walsh SB; Xu J; Afaq F; Elmets CA; Athar M
Biochem Biophys Res Commun; 2012 Aug; 425(2):177-81. PubMed ID: 22820192
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFβ signaling pathway.
Walsh SB; Xu J; Xu H; Kurundkar AR; Maheshwari A; Grizzle WE; Timares L; Huang CC; Kopelovich L; Elmets CA; Athar M
Mol Carcinog; 2011 Jul; 50(7):516-27. PubMed ID: 21308804
[TBL] [Abstract][Full Text] [Related]
14. STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma.
Naher L; Kiyoshima T; Kobayashi I; Wada H; Nagata K; Fujiwara H; Ookuma YF; Ozeki S; Nakamura S; Sakai H
Int J Oncol; 2012 Nov; 41(5):1577-86. PubMed ID: 22922995
[TBL] [Abstract][Full Text] [Related]
15. [The anti-proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells].
Yang AY; Liu JQ; Cai YN; Fang MY; Yang L; Chen M; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1003-1007. PubMed ID: 32023730
[No Abstract] [Full Text] [Related]
16. Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.
Jacków J; Rami A; Hayashi R; Hansen C; Guo Z; DeLorenzo D; Pappalardo A; Alvarez Cespedes D; Kim AL; Perez-Lorenzo R; Owens DM; Christiano AM
J Invest Dermatol; 2021 Apr; 141(4):942-946. PubMed ID: 33069729
[No Abstract] [Full Text] [Related]
17. Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients.
Mühleisen B; Petrov I; Frigerio S; Dziunycz P; French LE; Hofbauer GF
Arch Dermatol; 2012 Jun; 148(6):697-703. PubMed ID: 22508773
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract][Full Text] [Related]
19. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD
Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
